W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

BioNTech reaches agreement to get a non-exclusive license for mRNA-based Covid-19 and/or influenza products and resolve patent litigation with CureVac & GSK: Mainz, Germany Monday ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA Platform was estimated at US$152.0 Billion in 2024 and is ...

Discover key insights from Roivant Sciences' Q1 2025 earnings call, including brepocitinib DM data milestones, financial strength, and strategic ...

Q1 2025 Management View CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," ...

Are women somehow missing from the future of innovation? New research suggests that gender bias may be quietly shaping the ...

Lack of mRNA funding could pose a national security risk; CureVac, GSK settle mRNA suit against Pfizer, BioNTech; Gilead confident in HIV prevention drug prospects.

Roivant (Nasdaq: ROIV) today reported its financial results for the first quarter ended June 30, 2025, and provided a business ...

NIH Director Jay Bhattacharya offered an explanation for the cancellation of mRNA vaccine contracts that didn't align with ...

Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.